Explore 13641 medications in our directory, and growing.
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

At a Glance

Orilissa (elagolix) is FDA-approved for the management of moderate to severe pain associated with endometriosis in premenopausal women.
This is a brand drug with no generic or biosimilar.
Active ingredient: Elagolix Sodium.
Available as a prescription only.
Administration route: Oral.
Typical oral doses are 150 mg once daily or 200 mg twice daily, with the strength and duration chosen based on symptom severity and risk factors such as low bone mineral density.

See Your Ranked Personalized Treatments

A graphic depicting a sample medication report that registered members can run.
An image representing ORAL administration route of this drug.

How It Works

  • Orilissa is a gonadotropin-releasing hormone (GnRH) antagonist that acts on the pituitary gland in the brain.
  • It lowers the levels of estrogen and other hormones that drive endometriosis activity and pain.
  • By reducing these hormones, it helps lessen endometriosis-related pelvic pain, painful periods, and pain with sex.
.

Treatment and Efficacy

Approved indications: Orilissa is FDA-approved to treat moderate to severe pain associated with endometriosis in premenopausal women, including menstrual pelvic pain, non-menstrual pelvic pain, and pain with sexual intercourse.

Off-label uses: Limited research has explored elagolix for other hormone-dependent gynecologic conditions (such as heavy menstrual bleeding due to fibroids), but for fibroids the related drug Oriahnn—not Orilissa—is specifically approved; any off-label use of Orilissa is based on small studies or extrapolation and should be considered to have low-to-moderate evidence and used only under specialist guidance.

Efficacy expectations and onset: Many patients notice some pain relief within the first 1–2 months, with greater improvements typically seen by 3 months of continuous use; clinical trials showed significant reductions in endometriosis-associated pain compared with placebo for both the 150 mg once-daily and 200 mg twice-daily regimens.

Typical outcomes and comparison: Orilissa can reduce the frequency and intensity of pelvic pain, painful periods, and pain with sex, and can decrease use of rescue pain medicines, but it may not completely eliminate symptoms and responses vary between individuals; compared with some older hormonal options (such as continuous oral contraceptives or GnRH agonists), Orilissa offers oral dosing, more rapid onset and offset of effect, and avoids the initial symptom flare seen with GnRH agonists, but it carries important limitations on duration of use due to bone mineral density loss.

A graphic depicting a sample medication report that registered members can run.
.

Dosage and Administration

Typical dosing and how to take: For many women with moderate endometriosis pain, the usual dose is 150 mg by mouth once daily for up to 24 months; for more severe pain, 200 mg by mouth twice daily is often used but is typically limited to a shorter duration (such as up to 6 months) because of greater bone-mineral-density loss risk; tablets can be taken with or without food and should be swallowed whole at about the same times each day.

Special dosing instructions: The total allowed duration and choice of dose depend on factors such as baseline bone density, liver function, and other risk factors, so prescribers may order bone density testing before or during therapy and may limit or avoid repeat courses; patients with moderate liver impairment may require a lower dose or shorter treatment period, and Orilissa is not recommended for severe liver impairment.

Missed dose guidance: If a dose is missed, it is generally taken as soon as remembered on the same day unless it is almost time for the next scheduled dose, in which case the missed dose is skipped and the regular schedule resumed; doses should not be doubled to make up for a missed tablet.

Overdose: In case of suspected overdose, patients should contact a poison control center or seek emergency medical care immediately, bringing the medication container if possible, as treatment will focus on monitoring and managing symptoms and supporting vital functions.

.

Safety and Side Effects

Common side effects: Frequently reported effects include hot flashes or night sweats, headache, nausea, trouble sleeping, mood changes, and changes in menstrual bleeding (lighter, irregular, or absent periods); these often begin in the first weeks as estrogen levels fall and are usually mild to moderate but can be bothersome for some people.

Serious or rare adverse effects: Serious risks include decreased bone mineral density that may not fully recover after stopping, liver enzyme elevations, and rare severe mood changes including suicidal thoughts or behavior; any signs of severe depression, persistent or worsening mood changes, yellowing of the skin or eyes, dark urine, severe abdominal pain, or heavy or unusual vaginal bleeding require prompt medical attention.

Warnings and precautions: Orilissa should not be used during pregnancy because it can harm a developing fetus and is contraindicated in women who are pregnant or with known osteoporosis, severe liver impairment, or certain liver diseases; effective non-hormonal contraception is recommended during treatment and for at least one week after the last dose, and use during breastfeeding is generally not recommended due to lack of data.

Age limits and organ function: Orilissa is intended for premenopausal adult women and is not established or recommended for use in children or in women after natural menopause; dose adjustments or avoidance may be needed in people with moderate liver impairment or certain other medical conditions, as directed by a clinician.

Safety compared with other options: Compared with GnRH agonist injections, Orilissa avoids an initial hormone “flare” and is easier to stop quickly, but like other estrogen-lowering therapies it carries risks of hot flashes, mood changes, and bone loss, so duration is usually limited (for many patients to 24 months or less, depending on dose and risk factors).

Side-effect reporting and safety updates: Patients in the United States can report side effects to the FDA MedWatch program or to the manufacturer, and updated safety information is available through FDA drug labels and safety communications as well as from prescribing healthcare professionals.

A graphic depicting a sample medication report that registered members can run.
.

Interactions and Precautions

Drug and supplement interactions: Orilissa is affected by and can affect certain liver enzymes and transporters, so strong OATP1B1 inhibitors (such as cyclosporine and gemfibrozil) and some other medicines may significantly raise elagolix levels and are contraindicated or require dose adjustments; it can also interact with some hormonal contraceptives, certain seizure medicines, rifampin, and other drugs, so all prescription and over-the-counter medicines, vitamins, and herbal supplements (including St. John’s wort) should be reviewed with a clinician and pharmacist.

Food, alcohol, and procedures: Orilissa has no major food restrictions and may be taken with or without meals, but heavy alcohol use may worsen liver risk and mood changes and should be minimized or avoided; there are no specific known interactions with imaging contrast agents, but the full medication list should always be shared before any procedure.

Conditions and co-medications that require caution: Use requires special caution or may be inappropriate in women with osteoporosis or significant risk for bone loss, a history of severe depression or suicidal thoughts, liver disease, or heavy or unexplained vaginal bleeding; care is also needed when combining with other medicines that lower estrogen or affect bone density.

Monitoring needs: Clinicians may monitor for mood changes, menstrual pattern changes, and symptoms of liver problems, and may order blood tests for liver enzymes and, in some patients, bone mineral density testing before or during treatment; regular follow-up visits help ensure benefits continue to outweigh risks and allow adjustment or discontinuation if problems arise.

A graphic depicting a sample medication report that registered members can run.
.

Common Questions and Answers

Q: How long does it take for Orilissa to start relieving endometriosis pain?
A: Some women notice improvement within a few weeks, but it often takes 1–2 months to see clear benefits, with maximum pain relief typically reached after about 3 months of regular use.

Q: Will my periods stop completely while I am taking Orilissa?
A: Many women have lighter or irregular periods and some may stop having periods while on Orilissa, but patterns vary and any very heavy, prolonged, or unusual bleeding should be discussed with a healthcare provider.

Q: Can I become pregnant while taking Orilissa and what contraception should I use?
A: Pregnancy can still occur on Orilissa and the drug may harm a fetus, so effective non-hormonal birth control (such as condoms or a copper IUD) is recommended during treatment and for at least one week after the last dose unless your clinician advises otherwise.

Q: How long can I safely stay on Orilissa?
A: Because Orilissa can reduce bone mineral density, higher-dose regimens are usually limited to short-term use (often around 6 months) and lower-dose regimens are generally limited to about 24 months, with the exact duration tailored by your clinician based on your risks and response.

Q: What happens to my symptoms after I stop taking Orilissa?
A: Hormone levels gradually return toward baseline after stopping Orilissa, so menstrual cycles typically resume within a few weeks to months and endometriosis symptoms may return over time, which is why ongoing follow-up with your gynecologist is important to plan long-term management.

Better Treatment, Lower Cost – No Catch.

Find safer, more effective medications with fewer side effects – often for less money. It’s fast, free, and personalized. Learn More →

.

Disposal Guidance

Storage: Store Orilissa tablets at room temperature (generally 68°F to 77°F / 20°C to 25°C), away from excess heat, moisture, and direct light, and keep them in the original container with the lid tightly closed and out of reach of children and pets.

Disposal: Do not flush Orilissa down the toilet or pour it into drains unless instructed; instead, use a drug take-back program if available or follow local guidance for mixing unused tablets with an undesirable substance (such as coffee grounds or cat litter), sealing in a bag or container, and placing in household trash.

Content last updated on December 19, 2025. Always consult a qualified health professional before making any treatment decisions or taking any medications. Review our Terms of Service for full details.